Biologics News

MANCHESTER — Results of a small, randomized controlled pilot study that involved mechanobiologic and clinical assessments showed that platelet-rich plasma improved healing in acute Achilles tendon tears that were either percutaneously sutured or nonoperatively treated.

Researchers at the University of Pennsylvania have developed a new generation of nanofibrous scaffolds for tendon, ligament and knee meniscus tissue regeneration — tunable 3-D composite nanofibrous scaffolds.

According to the results of this study, 20% of the Australian population aged 45 years and older consumes glucosamine.

Researchers at Arizona State University and the National Aeronautics and Space Administration are using isotopic analysis to measure bone loss — and have found it to be more sensitive, as well as safer for patients.

Insertion of platelet-rich plasma gel to patellar tendon harvest sites improved healing and reduced postoperative pain in patients undergoing anterior cruciate ligament reconstruction in a recent study.

K2M Inc. announced an expansion of the company’s biologics offering with the launch of its VESUVIUS Osteobiologic Systems and new additions to its VIKOS Allograft Systems.

Researchers found no demonstrable effect on tendon healing, tendon vascularity, manual muscle strength or clinical rating scales when platelet-rich fibrin matrix was applied to the tendon-bone interface at the time of rotator cuff repair, according to this study published in The American Journal of Sports Medicine.

In patients with chronic rotator cuff tears, applying leucocyte platelet-rich fibrin increased vascularization following arthroscopic repairs, but did not improve shoulder function or tendon healing rates, according to a presentation at the American Shoulder and Elbow Surgeons 2012 Open Meeting.

SAN DIEGO – Platelet-rich plasma does not improve chronic non-insertional Achilles tendinosis, according to a researcher who presented at the American Orthopaedic Foot and Ankle Society Annual Meeting, here.

In a study presented at the European League Against Rheumatism Annual Congress, researchers demonstrated inequalities in access to biologics for the treatment of rheumatoid arthritis across 46 European countries — with 22% of countries having no biologics reimbursed whatsoever.